Bone Marrow Transplantation News

SAN DIEGO — Patients with relapsed large B-cell lymphoma who achieved a complete remission had a reduced relapse rate and improved PFS with autologous transplant, according to study findings presented at ASH Annual Meeting and Exposition.

Reduced-intensity haploidentical-bone marrow transplant showed durable donor engraftment at 2-years follow-up with low mortality among adults with severe sickle cell disease, according to study results.

SAN DIEGO — Axatilimab conferred clinically meaningful and durable responses at three dose levels among individuals with chronic graft-versus-host disease, randomized study results showed.

Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 9-12 in San Diego.

Three physicians have been elected to serve in leadership roles on ASH’s executive committee.

The FDA announced several regulatory actions.

President Joe Biden today announced his intention to appoint oncologist, researcher and educator, W. Kimryn Rathmell, MD, PhD, as director of the NCI.

Bioengineering company Ossium Health, which is developing the first bank of bone marrow collected from organ donors, has partnered with the National Marrow Donor Program/Be The Match to increase access to lifesaving bone marrow.

This blog post provides answers to important questions about the upcoming respiratory viral seasons.

The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into peripheral blood during collection for subsequent autologous transplantation in individuals with multiple myeloma.